Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the ...

为探究 UDCA 对肥胖、高血压等慢性疾病的影响，相关研究人员开展关于 UDCA 对人体测量指标、血压和炎症影响的研究，发现其可改善 BMI 和 DBP，但会升高 SBP。该研究为临床治疗提供参考，推荐科研读者阅读。 在当今社会，肥胖、高血压和代谢综合征等慢性疾病 ...

UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg – and recommended marketing authorization for treating non-alcoholic fatty liver disease (NAFLD). NAFLD, the most prevalent liver disease, affects ...